Alexander Haug
Alexander Haug
Associate Professor and Deputy Director of the Division of Nuclear Medicine, Medical University of
Email verificata su - Home page
Citata da
Citata da
Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation
B Sangro, L Carpanese, R Cianni, R Golfieri, D Gasparini, S Ezziddin, ...
Hepatology 54 (3), 868-878, 2011
Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival
RT Hoffmann, PM Paprottka, A Schön, F Bamberg, A Haug, EM Dürr, ...
Cardiovascular and interventional radiology 35 (1), 105-116, 2012
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours
A Haug, CJ Auernhammer, B Wängler, R Tiling, G Schmidt, B Göke, ...
European journal of nuclear medicine and molecular imaging 36 (5), 765-770, 2009
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor–mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors
AR Haug, CJ Auernhammer, B Wängler, GP Schmidt, C Uebleis, B Göke, ...
Journal of nuclear medicine 51 (9), 1349-1356, 2010
In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors
A Rominger, T Saam, E Vogl, C Übleis, C la Fougère, S Förster, A Haug, ...
Journal of nuclear medicine 51 (2), 193-197, 2010
Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG–PET–CT
GP Schmidt, A Baur-Melnyk, A Haug, V Heinemann, I Bauerfeind, ...
European journal of radiology 65 (1), 47-58, 2008
The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors
AR Haug, R Cindea-Drimus, CJ Auernhammer, M Reincke, B Wängler, ...
Journal of nuclear medicine 53 (11), 1686-1692, 2012
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma
FT Kolligs, JI Bilbao, T Jakobs, M Iñarrairaegui, JM Nagel, M Rodriguez, ...
Liver international 35 (6), 1715-1721, 2015
Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma
C la Fougère, W Hundt, N Bröckel, T Pfluger, A Haug, B Scher, M Hacker, ...
European journal of nuclear medicine and molecular imaging 33 (12), 1417-1425, 2006
Current status of theranostics in prostate cancer
I Virgolini, C Decristoforo, A Haug, S Fanti, C Uprimny
European journal of nuclear medicine and molecular imaging 45 (3), 471-495, 2018
Detection of low-grade prosthetic joint infections using 99mTc-antigranulocyte SPECT/CT: initial clinical results
V Graute, M Feist, S Lehner, A Haug, PE Müller, P Bartenstein, M Hacker
European journal of nuclear medicine and molecular imaging 37 (9), 1751-1759, 2010
Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue
W Rachinger, VM Stoecklein, NA Terpolilli, AR Haug, L Ertl, J Pöschl, ...
Journal of Nuclear Medicine 56 (3), 347-353, 2015
Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres
PM Paprottka, RT Hoffmann, A Haug, WH Sommer, F Raeßler, CG Trumm, ...
Cardiovascular and interventional radiology 35 (2), 334-342, 2012
Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer
GP Schmidt, A Baur-Melnyk, A Haug, S Utzschneider, CR Becker, R Tiling, ...
European radiology 19 (6), 1366-1378, 2009
18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer
AR Haug, BPT Donfack, C Trumm, CJ Zech, M Michl, RP Laubender, ...
Journal of Nuclear Medicine 53 (3), 371-377, 2012
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma
R Golfieri, JI Bilbao, L Carpanese, R Cianni, D Gasparini, S Ezziddin, ...
Journal of hepatology 59 (4), 753-761, 2013
PSMA ligand PET/MRI for primary prostate cancer: staging performance and clinical impact
B Grubmüller, P Baltzer, S Hartenbach, D D’Andrea, TH Helbich, ...
Clinical Cancer Research 24 (24), 6300-6307, 2018
Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer
WP Fendler, DBP Tiega, H Ilhan, PM Paprottka, V Heinemann, TF Jakobs, ...
Journal of Nuclear Medicine 54 (8), 1202-1208, 2013
Whole-body MRI and PET-CT in the management of cancer patients
GP Schmidt, AR Haug, SO Schoenberg, MF Reiser
European radiology 16 (6), 1216-1225, 2006
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy–diagnostic performance and impact on therapeutic decision-making
B Grubmüller, P Baltzer, D D’andrea, S Korn, AR Haug, M Hacker, ...
European journal of nuclear medicine and molecular imaging 45 (2), 235-242, 2018
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20